Slope, a site-first organization, ‘eliminating the chaos’ impacting clinical trials has joined CancerX as a founding member of The White House’s national Cancer Moonshot.
Artificial intelligence (AI) biotech company, Owkin, has invested $50million in a project that will use spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors.
Adede is a seasoned computer scientist and data professional known for providing high quality service whilst employing her multi talents which include efficiency, analytical thinking, and fast learning.
Research has reinforced the efficacy of Lumakras (sotorasib), a small molecule inhibitor in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).
The development of small molecule antivirals that target viral RNA in Henipaviruses will benefit from a $1.7million grant from Open Philanthropy, a philanthropic funder prioritizing global health and wellbeing.
'Compelling and landmark' results will ‘fundamentally change’ the journey of patients with stage 2 and 3 early breast cancer, specifically those in need of new, well-tolerated options to prevent their cancer from coming back.
Encouraging clinical data has been released by Biovie, a company developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.
A London-based start-up that says clinical trials are ‘the biggest bottleneck to improving human health’ is launching a number of ‘breakthrough’ treatments for conditions including tinnitus, insomnia and progressive childhood short-sightedness.
A drug that has the ability to ‘transform the landscape’ for people living with metastatic colorectal cancer (CRC) has been granted priority review by the US Food and Drug Administration (FDA).
A company developing small molecule therapeutics targeting DNA Damage Response (DDR) in order to treat patients with a broad range of cancers has its first assay development customer.
The UK has the tools to become a life-sciences superpower but those thinking about taking part remain put off by the lack of financial motivation, a clinical trials start-up says.
TechBio company, Closed Loop Medicine Ltd, and pharmaceutical company, Pharmanovia have entered into a co-development for precision medicine combination therapeutics.
By Charm Therapeutics gains investment from NVentures for cancer therapeutics
Charm Therapeutics has announced investment from NVentures – NVIDIA’s venture investment arm. This represents a major milestone for Charm and means it will be able to deliver more on its research and development (R&D) activities for novel oncology...
A previously announced research collaboration between Gilead Sciences and Arcus Biosciences that was focused on oncology has been expanded to include inflammatory diseases therapies.
Helmholtz Munich, one of Germany’s 19 research centers, that develops future solutions and technologies has selected DataDirect Networks (DDN) to accelerate its artificial intelligence (AI) driven discoveries.
AARDEX Group has joined forces with other industry companies to partner with a new project from The Digital Medical Society (DiMe) called Extending the Verification, Analytical Validation, and Clinical Validation – or V3+ Framework.
Results from a multinational trial of trifluridine/tipracil, known as Lonsurf, with or without bevacizumab in refractory metastatic colorectal cancer (mCRC) have resulted in statistically significantly and clinically meaningful improvements.
Rich Christie is chief medical officer at AiCure LLC. He is a firm believer in digtal biomarkers and the audio and visual biomarkers that can be captured through a front-facing camera. OSP inteviewed him to find about more about the changing landscape...
A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25).
The company announces plans to reorganize its business to focus on design-and-deployment engagements for on-site implementation of automated cloud labs.
A drug to treat a rare cancer that grows where the esophagus and stomach join has been accepted for review by the China National Medical Products Administration (NMPA).
The Institute for Population and Precision Health (IPPH) at the University of Chicago has joined private biotech company, Freenome, to become its partner as part of a study.
Unifying medicinal development processes and data within a connected technology ecosystem will enhance collaboration, two partnering companies using a development cloud have said.
A partnership was announced this week (April 11) between non-profit CureDuchenne and health technology company, PicnicHealth that will provide as much data as possible to researchers while helping patients navigate complex medical systems.
A breakthrough in rectal cancer treatment has been discovered through a collaboration between a cancer intelligence company and the world’s largest and oldest cancer center. It could put an end to the invasive surgery patients may have faced.
In its bid to what it says will make participation in clinical trials easier and more sustainable, Greenphire has revealed a patient-powered registry and it has also expanded a deal with Merck.
Progressive supranuclear-palsy (PSP) is a very rare brain disease and until recently, it was almost unheard of. Along with many neurodegenerative diseases, it has a high unmet medical need.
In the second and final part of an interview with Medable’s chief growth officer and women’s health champion, Sanskriti Thakur, discover her views on vital changes that need to be made. She discusses ways to ensure the importance of women’s roles in clinical...
The funding will be split between 17 US non-profit organizations this year, as the company reveals the broader progress it has made towards its long-term inclusion and diversity goals.
Positive data from a phase 2 clinical trial has proven the general mechanism of action of SK channel inhibition for treatment of atrial fibrillation (AF), an abnormal heart rhythm.
Charité – Universitätsmedizin Berlin, one of Europe’s largest university hospitals is collaborating with UK-based Exscientia to make use of an artificial intelligence-driven precision medicine platform in haematological cancers.
Guest article - Patient ID/recruitment and retention
The partners announce that they will combine to use artificial intelligence to improve the identification and enrolment of patients for clinical trials.
The two companies will come together to provide a ‘patient-centered solution’ for clinical research, combing uMotif’s patient engagement platform with ActiGraph’s wearable technology.
The pharma company provides funding to 24 community organizations throughout the US, as part of its newly created ‘Toward Health Equity Oncology Grant’.
One of the biggest questions being posed at this year's SCOPE summit, is whether the term 'decentralized clinical trials' will become redundant, as it forms the norm.
Steve Rosenberg has been a life science and healthcare executive for 40+ years and is currently CEO of uMotif. He commercialized the first integrated clinical technology suite at Phase Forward/Oracle. Top pharma and biotech executives depend on him for...
The Summit for Clinical Ops Executives (SCOPE) is back with a four-day schedule that digs into strategies and technologies for tackling the perpetual problem of patient recruitment.
A partnership to put an end to the ‘tremendously manual and time-consuming’ collection of clinical data and medication history has been formed between health information (HIN) Health Gorilla and DrFirst, a healthcare technology solutions consultancy.
OMEC.AI is the first startup to emerge from the alliance of pharma companies and investors that created AION Labs, and will focus on improving the efficacy and safety of drug candidates.
A representative from the biometric contract research organization explains how taking a ‘patient comes first’ attitude can lead to a range of improvements.
The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.